Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plecanatide - Bausch Health Companies

Drug Profile

Plecanatide - Bausch Health Companies

Alternative Names: GCRA; Guanilib; SP-304; TRULANCE

Latest Information Update: 18 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Callisto Pharmaceuticals
  • Developer Bausch Health Companies; Synergy Pharmaceuticals Inc
  • Class Anti-inflammatories; Irritable bowel syndrome therapies; Laxatives; Peptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 15 Jan 2021 Cipher Pharmaceuticals receives arbitration award (with regards to breach of contract with Bausch Health Companies) for plecanatide in Canada
  • 02 May 2020 Pooled efficacy data from phase III trials in Constipation and Irritable bowel syndrome presented at the Digestive Disease Week 2020 (DDW-2020)
  • 10 Oct 2019 Registered for Irritable bowel syndrome (In adults) in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top